A Q&A with Devora Allon
Devora Allon
Earlier this month, a federal jury in San Francisco absolved Gilead Sciences and Teva Pharmaceuticals of allegations they entered into an illegal pay-for delay settlement related to a pair of HIV treatments. GCR USA spoke to Kirkland & Ellis partner Devora Allon, co-lead counsel to Gilead, on how the drugmaker escaped the potential of facing billions in damages.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10